The pharmaceutical industry faces a significant shift as new trade barriers emerge. A U.S. administration mandate now requires generic drug manufacturers to establish production facilities within the United States or face steep tariffs. Starting in August 2028, imports of off-patent medicines could face a 100% tariff, with that figure set to double to 200% a year later. This policy follows an earlier move targeting innovative, patented medicines, which already face heavy duties unless companies adopt a plan for domestic production.
For Indian pharma companies, the path forward requires a shift in strategy. Many experts suggest that relying on the U.S. market under these conditions is no longer a sustainable long-term plan. Manufacturers must prioritize strengthening their domestic production capabilities and finding new export markets to reduce reliance on American demand. The pressure is on to adapt to these new trade constraints before the deadlines hit.
This development is part of a larger push by the administration to bring drug manufacturing back to American soil. As companies weigh the costs of relocating production, the global supply chain for generic drugs remains in a state of high uncertainty. Leaders in the sector are evaluating their options to maintain access to the U.S. market while balancing the costs of building new facilities or facing the impending tax penalties.